- CorMedix (NASDAQ:CRMD) on Monday stated it has entered right into a multi-year commercial provide contract with a worldwide healthcare firm for the availability of DefenCath to its services in U.S.
- The firm expects to initially goal the utilization of DefenCath in as much as 4,000 sufferers nationally, that might be prioritized primarily based upon medical want.
- CorMedix obtained NDA approval of DefenCath below the Limited Population Pathway for Antibacterial and Antifungal Drugs on November 15, 2023, and started commercialization of the product within the inpatient setting on April 15, 2024.
- CorMedix anticipates shipments for DefenCath below this agreement to start within the fourth quarter.
- CRMD is -2.08% to $5.64.
- Source: Press Release
Source: Seekingalpha